- Shire PLC
- Bausch Health Companies Inc.
- New River Pharmaceuticals Inc.
- Noven Pharmaceuticals Inc.
- Cephalon Inc.
- CTI BioPharma Corp.
- Forest Laboratories Inc.
- Gedeon Richter PLC
- ChemoCentryx Inc.
- Endo International PLC
- Enzon Pharmaceuticals Inc.
- NPS Pharmaceuticals Inc.
- Shire Human Genetic Therapies Inc.
- Supernus Pharmaceuticals Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Amgen Inc.
- Barr Laboratories Inc.
- Teva Pharmaceuticals USA Inc.
- Shire buys Transkaryotic Therapies for $1.57bn
- Shire to buy BioChem for $4bn in stock
- Shire licenses New River's ADHD candidate
- Noven, Shire enter another ADHD patch deal
- Shire acquires Noven's MethyPatch
- Cephalon buys Salmedix
- Cephalon buys two CTI divisions
- Forest licenses additional Gedeon Richter CNS compounds
- ChemoCentryx and Forest develop new CCR1 compounds; deal ends
- NPS / Enzon merger: withdrawn
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.